Absence of metabolic syndrome influence in rheumatoid arthritis activity

Abstract

Purpose: To identify the influence of Metabolic Syndrome (MS) in the response to treatment of patients with Rheumatoid Arthritis (RA). Methods: A cross-sectional, descriptive and analytical study was carried out from September 2013 to June 2014. Data collection was done through a research protocol developed by the authors at the ambulatory of Rheumatology of the Center of Medical Specialties (CEMEC) of the University Center of the State of Pará (CESUPA). We included female patients, older than 18 years and diagnosed with RA. All the smoking patients, with association with another autoimmune disease, nephropathy, hepatopathy, pregnant women, menopausal women and / or hormonal contraceptives were excluded from the study. Results:All the patients (27) were female, with a mean age of 40.89 ± 6.71 years and a disease time of 7.67 ± 6.02 years, with 21 patients (77.8%) presenting positive rheumatoid factor. Regarding the disease activity, the Erythrocyte Sedimentation Rate (ESR) presented a mean of 35.07 ± 17.43 mm / h and the C Rective Protein 13.85 ± 18.6 mg / dl, respectively. The mean Disease Activity Score of 28 joints was 4.69 ± 1.18. The frequency of MS found among patients was 33.3% (n = 9). In relation to the disease activity measured by DAS28 (4.38 ± 0.74 vs. 4.84 ± 1.34, p = 0.263), HSV (33.44 ± 13.87 mm / h vs. 35.94 ± 19, 39mm / h, p = 0.709) and CRP (19.33 ± 26.66 mg / dl vs. 11.11 ± 13.07 mg / dl, p = 0.403), there was no statistical difference between the SM and without MS (p = 0.263). Conclusion: The present study found that the presence of MS did not influence the response to treatment in patients with RA of CEMEC, not either related to disease activity, through laboratory tests or evaluated through the DAS28.